![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences firm centered on growing therapies for grownup and pediatric cancers with potential for Orphan Drug Designation, whereas additionally commercializing diagnostics, at the moment proclaims that Amy Broidrick, President and Chief Strategy Officer, and Tariq Arshad, MD, Chief Medical Officer, will current a company overview at the LD Micro Main Event XV. The convention is being held on October 25 – 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
| Event: | LD Micro Main Event XV |
| Presentation Date: | Wednesday, October 26, 2022 |
| Time: | 12:30 PM PT (Track 2) |
| Livestream: | https://me22.mysequire.com/ |
Qualigen administration crew members will probably be accessible for one-on-one conferences on Wednesday, October 26, 2022. The on-line livestream could be seen by going to https://me22.mysequire.com/, and clicking on Qualigen Therapeutics throughout the schedule. A brief registration is required to view.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc. is a diversified life sciences firm centered on growing therapies for grownup and pediatric most cancers, in addition to sustaining and increasing its core FDA-cleared FastPack® System, which has been used efficiently in diagnostics for over 20 years. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with robust binding affinity to G4s prevalent in most cancers cells; such binding may, by stabilizing the G4s towards “unwinding,” assist inhibit most cancers cell proliferation. The investigational compounds inside Qualigen’s household of RAS oncogene protein-protein interplay inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to trigger additional hurt. In idea, such mechanism of motion could also be efficient within the remedy of about one quarter of all cancers, together with sure types of pancreatic, colorectal, and lung cancers. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that’s overexpressed in most cancers cells; QN-247 could thereby have the option to inhibit the cells’ proliferation. QN-247 has proven promise in preclinical research for the remedy of acute myeloid leukemia (AML). In addition to its oncology drug pipeline, Qualigen has a longtime diagnostics business which manufactures and distributes proprietary and extremely correct fast blood testing programs to doctor workplaces and small hospitals for the administration of prostate most cancers and different illnesses and well being circumstances.
For extra details about Qualigen Therapeutics, Inc., please go to www.qualigeninc.com.
Forward-Looking Statements
This information launch incorporates forward-looking statements by Qualigen that contain dangers and uncertainties and replicate the Company’s judgment as of the date of this launch. These statements embrace these associated to the Company’s prospects and technique, together with statements associated to the event of QN-302 and the Company’s different therapeutic drug candidates. Actual occasions or outcomes could differ from the Company’s expectations. For instance, right here could be no assurance that the Company will probably be ready to efficiently develop any medication (together with QN-302, QN-247 and RAS-F); that preclinical improvement of the Company’s medication (together with QN-302, QN-247 and RAS-F, and the deprioritized infectious-disease drug candidate QN-165) will probably be accomplished on any projected timeline or will probably be profitable; that any medical trials will probably be authorised to start by or will proceed as contemplated by any projected timeline, or at all; that any future medical trial information will probably be favorable or that such trials will verify any enhancements over different merchandise or lack unfavourable impacts; that any medication will obtain required regulatory approvals (or Fast Track designation or Orphan Drug standing) or that they are going to be commercially profitable; that patents will situation on the Company’s owned and in-licensed patent purposes; that such patents, if any, and the Company’s at the moment owned and in-licensed patents would stop competitors; or that the Company will probably be ready to procure or earn enough working capital to full the event, testing and launch of the Company’s potential therapeutic merchandise (together with QN-302, QN-247 and RAS-F). The Company’s inventory worth might be harmed if any of the occasions or tendencies contemplated by the forward-looking statements fails to happen or is delayed or if any precise future occasion in any other case differs from expectations. Additional info regarding these and different threat elements affecting the Company’s business could be discovered within the Company’s prior filings with the Securities and Exchange Commission, together with its most up-to-date Form 10-Okay, all of which can be found at www.sec.gov.
The Company disclaims any intent or obligation to replace these forward-looking statements past the date of this information launch, besides as required by regulation. This warning is made below the protected harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
Source: Qualigen Therapeutics, Inc.
